• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

Hospira, Inc.

NYSE:HSP

$32.38 $0.40 (1.25%)

REAL-TIME: Last trade at

I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process

I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process

Hospira Carpuject Pre-filled Cartridges - Drug Alert: Products May Contain More Than the Intended Fill Volume

Anesthesia Drugs Market (2011 - 2015) - U.S. Market Entry Study

Hospira, Inc. Recalls Pain Drug Cartridges

Hospira Recalling One Lot of Pain Injections

Hospira Recalls Hydromorphone Injections that may Contain more than Intended Volume

Hospira recalls one lot of hydromorphone injection

Hospira Announces Recall On Over Fill Issue

Hospira recall looks similar to one in April, says Leerink

Hospira initiating recall of Hydrochloride Injection lot, FDA says

Orchid Chem Says from boardroom FY13 Contribution From Hospira Will Be 23-25%

Hospira Announces A Nationwide Voluntary Recall Of One Lot Of Hydromorphone Hydrochloride Injection 1 MG/ML, (C-II) 1 ML Fill In 2.5 ML Carpuject, That May Contain More Than T...

Hospira Convenes Its 2012 Annual Meeting of Shareholders

Hospira Convenes Its 2012 Annual Meeting of Shareholders

Hospira Convenes Its 2012 Annual Meeting of Shareholders

Hospira to Present at Upcoming Investor Conferences

Clinigen gains US FDA approval for Foscavir in HIV/AIDS-related cytomegalovirus

Rocky Mount Mending, But GMP ‘Issues’ Persist: Hospira CEO

Hospira, Inc. Restarts Troubled North Carolina Plant

While Europe enjoys cheap biotech drugs, U.S. waits on FDA

Hospira's 1Q results lower, but meet expectations

Hospira 1Q profit plummets 73 pct. as costs jump

Hospira Beats by a Penny, Backs View - Analyst Blog

Hospira Beats by a Penny, Backs View

Hospira's CEO Discusses Q1 2012 Results - Earnings Call Transcript

Sandoz Infringes Hospira Sedative Patent, U.S. Judge Rules

Hospira 1Q profit plummets 73 pct as costs jump

Hospira sees adjusted gross margin slightly weaker in second half

Hospira sees Q2 adjusted EPS relatively flat with Q1

Hospira profit slumps 73% on charges

Hospira profit slumps 73% on charges; revenue off

Hospira, Inc. (HSP) Tops Q1 EPS by 2c

Hospira sees FY12 CapEx $350M-$400M

Hospira sees FY12 cash flow from operations $575M-$625M

Hospira sees FY12 EPS $2.00-$2.30, consensus $2.16

Hospira reports Q1 EPS 47c, consensus 45c

Hospira Reports First-Quarter 2012 Results

Array BioPharma names Ron Squarer as CEO

Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference

See More Articles...